Log in or register to see all Alerts
New HTA Decisions in Scotland
December 2019
Drug name
MAVIRET® (glecaprevir/pibrentasvir)
Company
AbbVie Ltd
Decision date
11/11/2019
Therapeutic area
Infections
Therapeutic sub area
Hepatitis
Decision
Recommended
Indication
Treatment of chronic hepatitis C virus (HCV) infection in adolescents aged 12 to <18 years.
Decision Detail
Following an abbreviated submission, glecaprevir/pibrentasvir (Maviret®) is accepted for use within NHS Scotland.
Summary
The SMC has previously accepted glecaprevir/pibrentasvir for the treatment of chronic HCV infection in adults. This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of glecaprevir/pibrentasvir. This advice is contingent upon the continuing availability of the PAS in NHS Scotland or a list price that is equivalent or lower.